

Clinical Aspects of Chronic Obstructive Pulmonary Disease

GOLD ABCD assessment tool



Exacerbations

Definition: "Various clinical entities with multiple causes resulting in airflow limitation that is irreversible or at best poorly reversible"

Practical definition: clinical syndrome characterized by chronic respiratory symptoms, structural abnormalities (airways disease, emphysema, or both), lung-function impairment (e.g. poorly reversible airflow limitation), or any combination of these

Cornerstone of diagnosis is spirometry (typically with FEV1 <80% pred, FEV1:FVC <0.7)

Causes

- Smoking
- Genetic
- Environmental
- Biomass
- Occupational
- Air pollution

Further points

- COPD due to smoking associated with more severe emphysema and more rapid decline in FEV1 than COPD from biomass exposure
- COPD due to biomass characterized by airway-wall thickening and improved lung function after the use of bronchodilators
- Asthma may progress to fixed airways obstruction, and may also co-exist with COPD
 - More symptoms, exacerbations, and hospitalizations than smoking-associated COPD, but have a lower mortality rate



Flow (L/sec)

- Some further points on physiological measurements
- SaO2 <90% at rest requires ABG to assess need for supplemental O2 RV/TLC >0.35 indicates air trapping
- - When accompanied by dynamic hyperinflation, is a
- As hyperinflation worsens, both resting IC and inspiratory fraction decrease 6MWD <350m associated with increased mortality

Significance of decreased DLco (or KCO)

- Indirect measure of emphysema
- Predicts desaturation, pulmonary HTN, and lung cancer

Phenotyping and the role of chest CT

- Emphysema phenotype formerly referred to as "pink puffer" now defined by CT as MOLT (multi-organ loss of tissue) Associated with loss of mesenchymal tissue (bone, muscle, and fat).
 - Increased risk for lung cancer
 - Patients with heterogeneous, upper-lobe-predominant emphysema on CT are good candidates for bronchoscopic or surgical LVR
- Bronchitic phenotype formerly known as "blue bloater" display airway luminal narrowing and wall thickening on CT Increased cough, sputum (volume and purulence) and exacerbations
- Increased incidence of metabolic syndrome and coronary artery disease Increased mortality risk





Prognostic factors

Prognostic factor

Body mass index

(BMI)

(FEV,)

Obstruction

Dyspnoea

(MMRC scale)

BODE index score

36-49%

3

150 - 249

metres

+ 2 points + 3 points

≤ 35%

4

< 149

metres

+ 1 point

≤ 21

50-64%

2

- BODE index
- FEV1 (% pred)
- Intensity of dyspnea
- Cachexia
- Impairment of ADLs
- Exacerbation frequency, duration and need for hospitalization
 - Hx of exacerbations predicts future • exacerbations as well as mortality

250-349 Exercise capacity Especially two or more in a year or an (6-minute walk distance) metres episode requiring hospitalization

30%-50% have a bacterial cause		Up to 30% are viral		Frequent exacerbators identified by:	
1.	Haemophilus influenza	1.	Influenza	• +	Ax of exacerbations
2.	Streptococcus pneumonia	2.	Rhinovirus	• 9	Severe airflow limitation
3.	Moraxella catarrhalis			• F	Presence of GORD

AECOPD management concepts

- Nebulized SABA, short-acting anticholinergics may be added if required
- Systemic steroids (e.g. 40mg pred OD PO for 5d) improve airflow, gas exchange, symptoms
- Benefit of antibiotics highest in patients with severe exacerbations and purulent sputum
- Hospitalize if FEV1 <1L, hypoxemia, hypercapnia, significant comorbidity
- If SaO2 <90%, room air ABG indicated
- Hypoxemia without hypercapnia \rightarrow low-flow O2
- Target Pao2 >8kPa with SaO2 91-94%
- Persistent hypercapnia with pH <7.35 but >7.15 → consider NIV
- C/l's to NIV: unstable patient, shock, unprotected airway, agitation, craniofacial deformity
 - Consider invasive mechanical ventilation instead

Maintenance



Dr Oliver McElvaney, Beaumont Hospital

ITS HERMES FLASHCARD SERIES 2021

Pattern

- (inspiratory capacity)/TLC <0.25 associated with increased mortality
 - determinant of the severity of dyspnea.